Category: Healthcare & Pharmaceuticals

Clinical Trials Healthcare & Pharmaceuticals News

Eli Lilly Announces Positive Results from Two Phase 3 Studies of Jaypirca at ASH 2025

Eli Lilly and Company

Eli Lilly and Company is set to present “striking” new data at the 2025 ASH Annual Meeting, revealing a double victory for its BTK inhibitor, Jaypirca (pirtobrutinib). Results from two pivotal Phase 3 trials demonstrate that Jaypirca not only outperforms standard chemoimmunotherapy in first-line treatment but also meets non-inferiority benchmarks against the established drug ibrutinib. These findings could pave the way for Jaypirca to become a new standard of care for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) across multiple treatment settings.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

U.S. FDA Approves PADCEV® and KEYTRUDA® Combo for Patients with Bladder Cancer

pfizer news

The FDA has granted approval for PADCEV® plus KEYTRUDA® as a perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Clinical data reveals the combination reduces the risk of recurrence, progression, or death by 60% compared to surgery alone, marking a major shift in the standard of care.

Oncology Healthcare & Pharmaceuticals News

European Commission Approves Roche’s Subcutaneous Lunsumio for Relapsed or Refractory Follicular Lymphoma

Roche

European Commission has granted conditional approval for the subcutaneous version of Roche’s bispecific antibody, Lunsumio (mosunetuzumab). This new formulation for relapsed or refractory follicular lymphoma offers high rates of deep and durable responses while reducing treatment administration time from several hours to approximately one minute. This enhanced flexibility promises a better treatment experience for patients and streamlined care delivery in clinics.

Clinical Trials Autoimmune Diseases Healthcare & Pharmaceuticals News

New 48-Week Data Shows TREMFYA® (guselkumab) Substantially Inhibits Joint Damage in Psoriatic Arthritis

JohnsonAndJohnson

New long-term data from the Phase 3b APEX study confirms that TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to substantially inhibit the progression of structural joint damage in patients with active psoriatic arthritis, with results sustained through 48 weeks.

Business Healthcare & Pharmaceuticals News

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388

Merck MSD

Merck has announced a definitive agreement to acquire Cidara Therapeutics for approximately $9.2 billion in an all-cash deal. The strategic acquisition centers on Cidara’s lead candidate, CD388, a potentially first-in-class, long-acting antiviral designed for the universal prevention of influenza A and B, which is currently in Phase 3 trials. The transaction is expected to close in the first quarter of 2026.

Business Healthcare & Pharmaceuticals News

Merck Group Q3 2025: Strong Organic Growth Across All Sectors

merck group news

Merck delivered solid Q3 2025 results, achieving 5.2% organic growth that successfully offset significant currency headwinds. This resilience was seen across all three business sectors, driven by strong demand for Process Solutions in Life Science, the new Rare Diseases franchise in Healthcare, and AI-driven demand for Semiconductor Solutions.

Genomics Artificial Intelligence Healthcare & Pharmaceuticals News

SOPHiA GENETICS and Complete Genomics Partner to Integrate AI Oncology Assays with New Sequencing Platform

SOPHiA GENETICS NEWS

SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics have announced a collaboration to broaden access to precision oncology testing. The partnership will integrate the AI-powered SOPHiA DDMâ„¢ platform with Complete Genomics’ new DNBSEQ-T1+ sequencing system. This will provide a streamlined, sample-to-report workflow for the renowned MSK-IMPACT® (solid tumor) and MSK-ACCESS® (liquid biopsy) assays.